Sogacin/TOCscan binds specifically to somatostatin receptors.

Sogacin/TOCscan is indicated for use with positron emission tomography (PET).

The following indications have been particularly documented:

• Detection of the primary occult neuroendocrine tumour when a metastasis of neuroendocrine tumour has been demonstrated or when the serum concentration of a specific marker is increased,
• Characterisation of bronchial mass as neuroendocrine tumour when other diagnostic modalities have not been conclusive,
• Characterisation, initial staging, detection in case of biochemical recurrence and restaging of neuroendocrine tumours of the foregut, including in the thymus or the bronchi,
• Characterisation, initial staging, detection in case of biochemical recurrence and restaging of neuroendocrine tumours of the midgut, when 6-fluoro-(¹⁸F)-L-dihydroxyphenylalanine is not available or when PET with 6-fluoro-(¹⁸F)-L-dihydroxyphenylalanine is non-conclusive,
• As an adjunct to anatomic imaging in pre-therapeutic evaluation of meningeoma.

Tumours which do not bear somatostatin receptors will not be visualised with Sogacin/TOCscan.